Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Matsuyama, M. Iwadate, M. Kondo, M. Saitoh, A. Hanyu, K. Shimizu, H. Aburatani, H. Mishima, T. Imamura, K. Miyazono, K. Miyazawa (2003)
SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.Cancer research, 63 22
B. Schiff, A. McMurphy, S. Jasser, M. Younes, Dao Doan, O. Yiğitbaşı, Seungwon Kim, Ge Zhou, M. Mandal, B. Bekele, F. Holsinger, S. Sherman, Sai-Ching Yeung, Adel El-Naggar, Adel El-Naggar, J. Myers (2004)
Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid CancerClinical Cancer Research, 10
K. Beppu, Jerry Jaboine, M. Merchant, C. Mackall, C. Thiele (2004)
Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.Journal of the National Cancer Institute, 96 1
R. Aasland, L. Akslen, J. Varhaug, J. Lillehaug (1990)
Co‐expression of the genes encoding transforming growth factor‐α and its receptor in papillary carcinomas of the thyroidInternational Journal of Cancer, 46
F. Sirotnak (2003)
Studies with ZD1839 in preclinical models.Seminars in oncology, 30 1 Suppl 1
R. Dagher, M. Cohen, G. Williams, Mark Rothmann, J. Gobburu, G. Robbie, Atiqur Rahman, Gang Chen, Ann Staten, D. Griebel, R. Pazdur (2002)
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 10
J. Kurebayashi, T. Otsuki, Tang Ck, M. Kurosumi, S. Yamamoto, K. Tanaka, M. Mochizuki, H. Nakamura, H. Sonoo (1999)
Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6British Journal of Cancer, 79
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
D. George (2002)
Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate.Urology, 60 3 Suppl 1
V. Pushkarev, V. Pushkarev, Starenki Dv, V. Saenko, H. Namba, J. Kurebayashi, M. Tronko, Shunichi Yamashita (2004)
Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells.Endocrinology, 145 7
T. Barber, B. Vogelstein, K. Kinzler, V. Velculescu (2004)
Somatic mutations of EGFR in colorectal cancers and glioblastomas.The New England journal of medicine, 351 27
MH Cohen, GA Williams, R Sridhara, G Chen, WD McGuinn, D Morse, S Abraham, A Rahman, C Liang, R Lostritto, A Baird, R Pazdur (2004)
United States food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tabletsClin Cancer Res, 10
F. Cappuzzo, F. Hirsch, E. Rossi, S. Bartolini, G. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, V. Ludovini, E. Magrini, V. Gregorc, C. Doglioni, A. Sidoni, M. Tonato, W. Franklin, L. Crinò, P. Bunn, M. Varella-Garcia (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.Journal of the National Cancer Institute, 97 9
The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society All-Trans-Retinoic Acid Modulates Expression Levels of Thyroglobulin and Cytokines in a New Human Poorly Differentiated Papillary Thyroid Carcin
Akira Hirata, F. Hosoi, M. Miyagawa, Shu-ichi Ueda, S. Naito, T. Fujii, M. Kuwano, M. Ono (2005)
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.Cancer research, 65 10
J. Dziba, K. Ain (2004)
Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.The Journal of clinical endocrinology and metabolism, 89 5
(2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
J. Albanell, F. Rojo, S. Averbuch, A. Feyereislova, J. Mascaró, R. Herbst, P. LoRusso, D. Rischin, S. Sauleda, J. Gee, R. Nicholson, J. Baselga (2002)
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 1
Gorgoulis, D. Aninos, C. Priftis, C. Evagelopoulou, A. Karameris, Panagiotis Kanavaros, Spandidos Da (1992)
Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors.In vivo, 6 3
Thomas Lynch, Daphne Bell, Raffaella Sordella, S. Gurubhagavatula, Ross Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, David Louis, David Christiani, Jeffrey Settleman, Daniel Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
K. Ain (1998)
Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches.Thyroid : official journal of the American Thyroid Association, 8 8
H. Kunisue, J. Kurebayashi, T. Otsuki, C. Tang, M. Kurosumi, S. Yamamoto, K. Tanaka, H. Doihara, N. Shimizu, H. Sonoo (1999)
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2British Journal of Cancer, 82
M. Kris, R. Natale, R. Herbst, T. Lynch, D. Prager, C. Belani, J. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, K. Albain, D. Cella, M. Wolf, S. Averbuch, J. Ochs, A. Kay (2003)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.JAMA, 290 16
J. Kurebayashi, M. Kurosumi, H. Sonoo (1995)
A new human breast cancer cell line, KPL-1 secretes tumour-associated antigens and grows rapidly in female athymic nude mice.British Journal of Cancer, 71
J Kurebayashi, K Tanaka, T Otsuki, T Moriya, H Kunisue, M Uno, H Sonoo (2000)
All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1J Clin Endocrinol Metab, 85
M. Ranson, L. Hammond, D. Ferry, M. Kris, A. Tullo, P. Murray, V. Miller, S. Averbuch, J. Ochs, C. Morris, A. Feyereislova, H. Swaisland, E. Rowinsky (2002)
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 9
S. Okubo, J. Kurebayashi, T. Otsuki, Yutaka Yamamoto, Katsuhiro Tanaka, H. Sonoo (2004)
Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cellsBritish Journal of Cancer, 90
C. Arteaga (2002)
Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia.Seminars in oncology, 29 5 Suppl 14
Katsuhiro Tanaka, H. Sonoo, J. Kurebayashi, T. Nomura, Sumiko Ohkubo, Yutaka Yamamoto, S. Yamamoto (2002)
Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 5
D. Matei, D. Chang, M. Jeng (2004)
Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor α and Akt InactivationClinical Cancer Research, 10
Alexei Podtcheko, A. Ohtsuru, S. Tsuda, H. Namba, V. Saenko, M. Nakashima, N. Mitsutake, S. Kanda, J. Kurebayashi, S. Yamashita (2003)
The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.The Journal of clinical endocrinology and metabolism, 88 4
L. Jackson (1978)
Chromosomes and cancer: current aspects.Seminars in oncology, 5 1
E. Buchdunger, T. O'reilly, J. Wood (2002)
Pharmacology of imatinib (STI571).European journal of cancer, 38 Suppl 5
M. Cohen, Grant Williams, R. Sridhara, Gang Chen, W. Mcguinn, D. Morse, S. Abraham, Atiqur Rahman, Chen Liang, R. Lostritto, A. Baird, R. Pazdur (2004)
United States Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 10
Y. Nobuhara, N. Onoda, Y. Yamashita, M. Yamasaki, K. Ogisawa, T. Takashima, T. Ishikawa, K. Hirakawa (2005)
Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell linesBritish Journal of Cancer, 92
J. Kurebayashi, T. Otsuki, Katsuhiro Tanaka, Yutaka Yamamoto, T. Moriya, H. Sonoo (2003)
Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2.Thyroid : official journal of the American Thyroid Association, 13 3
J. Baselga, D. Rischin, M. Ranson, H. Calvert, E. Raymond, D. Kieback, S. Kaye, L. Gianni, A. Harris, T. Björk, S. Averbuch, A. Feyereislova, H. Swaisland, F. Rojo, J. Albanell (2002)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 21
S. Moulder, F. Yakes, S. Muthuswamy, R. Bianco, J. Simpson, C. Arteaga (2001)
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.Cancer research, 61 24
G. Fang, C. Kim, C. Perkins, Nimmanapalli Ramadevi, E. Winton, S. Wittmann, K. Bhalla (2000)
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.Blood, 96 6
Purpose : Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies. Although multidisciplinary treatments have been introduced, patients with this disease rarely survive longer than 1 year. These findings prompted us to investigate the antitumor activity of molecular targeting agents in thyroid cancer cells. Methods : Two tyrosine kinase inhibitors, gefitinib and imatinib, were tested in a poorly differentiated thyroid cancer cell line, KTC-1, and two ATC cell lines, KTC-2 and KTC-3. Results : All cell lines expressed not only a target molecule of gefitinib, HER1, but also a cognate receptor, HER2. They also expressed target molecules of imatinib, c-ABL and platelet-derived growth factor receptors at various levels. Both agents had modest antitumor activity in these cell lines. Combined treatment with gefitinib and imatinib led to an additional antitumor effect. Each agent induced apoptosis and their combined treatment enhanced apoptosis associated with the down-regulation of antiapoptotic proteins, Bcl-2 and Bcl-xL. Moreover, their combined treatment additionally inhibited the growth of KTC-3 xenografts in nude mice. Conclusions : These are the first findings to suggest that both gefitinib and imatinib have antitumor activity against ATC cells and that their combined use has greater activity than either drug alone.
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Oct 1, 2006
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.